A Single-center, Randomized, 6-month, Non-inferiority Study to Compare the Safety and Efficacy of TICAgreLor mONotherapy Versus Dual Antiplatelet Therapy in Chronic Coronary Syndrome Patients Post Percutaneous Coronary IntErvention (TICALONE)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 80
Healthy Volunteers: f
View:
• Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome
• The patient has provided written informed consent as approved by the ethics committee of the Shiraz University of Medical Sciences.
Locations
Other Locations
Islamic Republic of Iran
Cardiology Ward Shiraz University of Medical Sciences
RECRUITING
Shiraz
professor Kojuroi cardiology clinic
RECRUITING
Shiraz
Contact Information
Primary
javad UOM Kojuri, MD.MS
kojurij@yahoo.com
09171115083
Backup
javad UOM Kojuri, MD.MS.
kojurij@yahoo.com
09171115083
Time Frame
Start Date: 2024-08-01
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 5400
Treatments
Active_comparator: Clopidogrel and aspirin
Patients post PCI randomized to Aspirin 80 mg and clopidogrel 75 mg daily
Experimental: ticagrelor
Patients post PCI randomized to Ticagrelor 90 mg PO two times daily
Related Therapeutic Areas
Sponsors
Leads: Shiraz University of Medical Sciences